These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 20711172

  • 1. Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
    Abbas O, Richards JE, Mahalingam M.
    Mod Pathol; 2010 Nov; 23(11):1535-43. PubMed ID: 20711172
    [Abstract] [Full Text] [Related]

  • 2. Fibroblast-activation protein: valuable marker of cutaneous epithelial malignancy.
    El Khoury J, Kurban M, Kibbi AG, Abbas O.
    Arch Dermatol Res; 2014 May; 306(4):359-65. PubMed ID: 24595644
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Expression of p75 neurotrophin receptor in desmoplastic trichoepithelioma, infiltrative basal cell carcinoma, and microcystic adnexal carcinoma.
    Jedrych J, McNiff JM.
    Am J Dermatopathol; 2013 May; 35(3):308-15. PubMed ID: 23598854
    [Abstract] [Full Text] [Related]

  • 5. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.
    Sellheyer K, Nelson P, Kutzner H, Patel RM.
    J Cutan Pathol; 2013 Apr; 40(4):363-70. PubMed ID: 23398472
    [Abstract] [Full Text] [Related]

  • 6. Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery.
    Merritt BG, Snow SN, Longley BJ.
    Cutis; 2010 May; 85(5):254-8. PubMed ID: 20540416
    [Abstract] [Full Text] [Related]

  • 7. Does Immunohistochemistry Add to Morphology in Differentiating Trichoepithelioma, Desmoplastic Trichoepithelioma, Morpheaform Basal Cell Carcinoma, and Microcystic Adnexal Carcinoma?
    Mohanty SK, Sardana R, McFall M, Pradhan D, Usmani A, Jha S, Mishra SK, Sampat NY, Lobo A, Wu JM, Balzer BL, Frishberg DP.
    Appl Immunohistochem Mol Morphol; 2022 Apr 01; 30(4):273-277. PubMed ID: 35384877
    [Abstract] [Full Text] [Related]

  • 8. Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin.
    East E, Fullen DR, Arps D, Patel RM, Palanisamy N, Carskadon S, Harms PW.
    Am J Dermatopathol; 2016 Oct 01; 38(10):744-50. PubMed ID: 27043336
    [Abstract] [Full Text] [Related]

  • 9. PHLDA1 (TDAG51) is a follicular stem cell marker and differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma.
    Sellheyer K, Krahl D.
    Br J Dermatol; 2011 Jan 01; 164(1):141-7. PubMed ID: 20846311
    [Abstract] [Full Text] [Related]

  • 10. Panel vs. single marker for discriminating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma.
    Vollmer RT.
    J Cutan Pathol; 2009 Feb 01; 36(2):283; author reply 284. PubMed ID: 19208081
    [No Abstract] [Full Text] [Related]

  • 11. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma?
    Katona TM, Perkins SM, Billings SD.
    J Cutan Pathol; 2008 Feb 01; 35(2):174-9. PubMed ID: 18190441
    [Abstract] [Full Text] [Related]

  • 12. Desmoplastic Trichoepithelioma: An Uncommon but Diagnostically Problematic Benign Adnexal Tumor.
    Bartoš V.
    Acta Dermatovenerol Croat; 2019 Dec 01; 27(4):282-284. PubMed ID: 31969246
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples.
    Tebcherani AJ, de Andrade HF, Sotto MN.
    Mod Pathol; 2012 Oct 01; 25(10):1345-53. PubMed ID: 22684216
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic utility of cytokeratin 17 immunostaining in morpheaform basal cell carcinoma and for facilitating the detection of tumor cells at the surgical margins.
    Anderson-Dockter H, Clark T, Iwamoto S, Lu M, Fiore D, Falanga JK, Falanga V.
    Dermatol Surg; 2012 Aug 01; 38(8):1357-66. PubMed ID: 22691048
    [Abstract] [Full Text] [Related]

  • 15. Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
    López JI, Errarte P, Erramuzpe A, Guarch R, Cortés JM, Angulo JC, Pulido R, Irazusta J, Llarena R, Larrinaga G.
    Hum Pathol; 2016 Aug 01; 54():100-5. PubMed ID: 27063470
    [Abstract] [Full Text] [Related]

  • 16. Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
    Köbel M, Kang EY, Lee S, Terzic T, Karnezis AN, Ghatage P, Woo L, Lee CH, Meagher NS, Ramus SJ, Gorringe KL.
    Histopathology; 2024 Jun 01; 84(7):1095-1110. PubMed ID: 38155475
    [Abstract] [Full Text] [Related]

  • 17. Stromelysin-3: a potent marker for histopathologic differentiation between desmoplastic trichoepithelioma and morphealike basal cell carcinoma.
    Thewes M, Worret WI, Engst R, Ring J.
    Am J Dermatopathol; 1998 Apr 01; 20(2):140-2. PubMed ID: 9557781
    [Abstract] [Full Text] [Related]

  • 18. Follicular stem cell marker PHLDA1 (TDAG51) is superior to cytokeratin-20 in differentiating between trichoepithelioma and basal cell carcinoma in small biopsy specimens.
    Sellheyer K, Nelson P.
    J Cutan Pathol; 2011 Jul 01; 38(7):542-50. PubMed ID: 21352265
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic accuracy of immunohistochemical markers in differentiation between basal cell carcinoma and trichoepithelioma in small biopsy specimens.
    Mostafa NA, Assaf M, Elhakim S, Abdel-Halim MRE, El-Nabarawy E, Gharib K.
    J Cutan Pathol; 2018 Nov 01; 45(11):807-816. PubMed ID: 29917261
    [Abstract] [Full Text] [Related]

  • 20. Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma.
    Hua X, Yu L, Huang X, Liao Z, Xian Q.
    Diagn Pathol; 2011 Nov 08; 6():111. PubMed ID: 22067528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.